Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Experimental cancer drug works differently than researchers originally thought
Experimental cancer drug works differently than researchers originally thought
Read also
Litfulo Phase III data support Pfizer’s push into systemic vitiligo treatment
Pfizer's Phase III trials demonstrate Litfulo's efficacy in nonsegmental vitiligo, supporting its plan to submit data to global regulatory authorities.
Bayer pledges $2.2bn to US manufacturing facility
Bayer has committed $2.2 billion to build a new, modular pharmaceutical manufacturing campus in Ohio, expected to serve global and domestic markets.
Click claims FDA okay for first-in-class schizophrenia DTx
Click Therapeutics received FDA clearance for Motivista, a digital therapeutic shown to significantly reduce negative symptoms in schizophrenia patients.
FDA Approval Opens New Treatment Path for ESR1-Mutated Breast Cancer
The FDA granted full approval to imlunestrant and abemaciclib for ESR1-mutated advanced breast cancer, shifting the treatment paradigm.
